Lamellar Biomedical has raised £5.75m in Series C Fund round to develop a range of pharmaceutical products based on its proprietary LAMELLASOME technology.

Lamellasomes mimics the functions of mucoous, which helps to keep out infection and provides lubrication which allows us to swallow or produce tears to lubricate the eyes.

The Bellshill-based life sciences company is currently developing a pipeline of novel patent-protected medical devices and pharmaceuticals, namely targeting dry eye disease (DED), radiotherapy-induced Xerostomia (dryness of mouth), and Cystic Fibrosis.

The latest funding round was led by existing investor Invesco Asset Management, acting as an agent on behalf of discretionary managed clients, backed with further support from the Scottish Investment Bank, the investment arm of Scottish Enterprise.

The latest funding will support commercialisation of Lamellar products.

Alec McLean, chief executive of Lamellar Biomedical, said: “We are pleased to have closed this Series C fund raising, which will allow us to generate further significant value from our pipeline of potentially groundbreaking LAMELLASOME based products.''